Hanseatic Management Services Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Hanseatic Management Services Inc. acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,183 shares of the company’s stock, valued at approximately $258,000.

Several other hedge funds have also modified their holdings of DYN. Mirae Asset Global Investments Co. Ltd. grew its stake in Dyne Therapeutics by 24.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock worth $812,000 after purchasing an additional 5,696 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Dyne Therapeutics during the first quarter valued at about $810,000. Lisanti Capital Growth LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter valued at about $2,459,000. Swiss National Bank grew its position in shares of Dyne Therapeutics by 41.5% in the 1st quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $2,419,000 after buying an additional 25,000 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $573,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Dirk Kersten sold 23,671 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the transaction, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John Cox bought 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at $264,320. This trade represents a -100.00 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 158,975 shares of company stock valued at $5,693,789. Corporate insiders own 20.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Piper Sandler restated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $43.00 to $35.00 in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.60.

Dyne Therapeutics Trading Up 4.2 %

Shares of NASDAQ:DYN opened at $29.81 on Thursday. The business’s 50-day simple moving average is $33.72 and its 200 day simple moving average is $34.94. Dyne Therapeutics, Inc. has a one year low of $7.93 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.02. On average, analysts expect that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.